357 results on '"Horowitz, Netanel A."'
Search Results
2. Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses
3. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
4. A prediction model for central venous catheter-related thrombosis in patients with newly-diagnosed acute myeloid leukemia: A derivation cohort analysis
5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
6. Flow-cytometry Assessment of DNA content Analysis and Immunophenotyping of Immune-cells in Lymph-node-specimens as Potential Diagnostic Signature of Aggressiveness in B-Non-Hodgkin Lymphomas
7. 2654. International Multi-Center Study Comparing the Effect of Obinutuzumab or Rituximab Treatment in Hematological Patients on COVID-19 Outcomes During the Omicron Surge
8. Hematopoietic Transplantation and Cellular Therapy in Acute Lymphoblastic Leukemia
9. Flow-cytometry Assessment of DNA content Analysis and Immunophenotyping of Immune-cells in Lymph-node-specimens as Potential Diagnostic Signature of Aggressiveness in B-Non-Hodgkin Lymphomas
10. An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
11. A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma
12. BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study
13. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
14. Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
15. Which patients should I transplant with acute lymphoblastic leukemia?
16. Working from home made possible in a health care facility - the experience of a tertiary hospital during the first Covid-19 wave
17. Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation
18. A higher BMI is positively associated with advanced neck lymphoma at diagnosis
19. In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression
20. Thrombosis in Pregnant Women with Hematological Malignancies: A Case-Based Review
21. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era
22. Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia
23. Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
24. Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
25. Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis
26. Thrombosis in Pregnant Women with Hematological Malignancies: A Case-Based Review.
27. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study
28. Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group
29. P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study
30. Non-Hodgkin lymphomas in pregnancy: Tackling therapeutic quandaries
31. Revisiting SARS-CoV-2 environmental contamination by patients with COVID-19: The Omicron variant does not differ from previous strains
32. Hematopoietic Cell Transplants for BCR/ABL Positive Acute Lymphocytic Leukemia
33. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients
34. In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression.
35. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study.
36. Reproductive organ involvement in non-Hodgkin lymphoma during pregnancy: a systematic review
37. Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
38. PL-25 Mechanisms coupling thrombomodulin to tumor dissemination
39. Brain-derived neurotrophic factor in hematological malignancies: From detrimental to potentially beneficial
40. Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study
41. Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
42. Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort
43. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma
44. Attenuated humoral immune response following anti‐SARS‐CoV‐2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis
45. Continuous Remote Patient Monitoring Shows Early Cardiovascular Changes in COVID-19 Patients
46. ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses
47. Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses
48. A 14-Year Experience in the Management of Patients with Acquired Immune Thrombotic Thrombocytopenic Purpura in Northern Israel: Rituximab Adjuvant Therapy in Patients with Refractory and Relapsed Disease Is Both Effective and Cost Beneficial
49. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
50. Author response: Precise staging of lymphoma duringpregnancy using MRI is not always crucial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.